AngioClast Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

AngioClast General Information

Description

Owner and operator of a biotechnology company. The company is focused on developing anti-cancer drugs for the treatment of brain cancer by utilizing molecular techniques.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • University of Cambridge
  • Cambridge
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AngioClast Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Startup
To view AngioClast’s complete valuation and funding history, request access »

AngioClast Executive Team (2)

Name Title Board Seat Contact Info
Juba Tsuladze Co-Founder & Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

AngioClast Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AngioClast Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Accelerate Cambridge Accelerator/Incubator 000 0000 000000 0
To view AngioClast’s complete investors history, request access »